ONTX 8-K filed 2026 · insiderdelta

Item 7.01 Regulation
FD Disclosure.

On May 27, 2026,
Traws Pharma, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its antiviral
program targeting the ongoing Hantavirus and Ebola Virus disease outbreaks. A copy of the Press Release is attahced as
Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated by reference into this Item
7.01.

The information included
in this Current Report under this Item 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for
the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange
Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Forward-Looking
Statements

This Current Report,
including Exhibit 99.1, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein,
the terms “anticipates,” “expects,” “estimates,” “believes,” “will” and similar
expressions, as they relate to the Company or its management, are intended to identify such forward-looking statements.

Forward-looking statements
in this Current Report, including Exhibit 99.1, or hereafter, including in other publicly available documents filed with the Securities
and Exchange Commission, reports to the stockholders of the Company and other publicly available statements issued or released by the
Company involve known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance
(financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed
or implied by such forward-looking statements. Such future results are based upon management’s reasonable estimates based upon
current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein
and in such other documents filed with the Securities and Exchange Commission, each of which could adversely affect the Company’s
business and the accuracy of the forward-looking statements contained herein.
ONTX Onconova Therapeutics, Inc. - 8-K

Item 7.01 - Regulation FD Disclosure

Item 9.01 - Financial Statements and Exhibits
